New imaging agent could spot recurrent brain metastases more accurately
NCT ID NCT06777433
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new imaging agent called RAD101, used with a PET scan, to see if it can better detect brain metastases that have come back after treatment. About 30 adults with certain cancers (like lung, breast, or melanoma) and suspected recurrent brain tumors will receive one dose of RAD101 and have a PET scan. The results will be compared to standard MRI scans to see if RAD101 improves detection of tumor recurrence versus treatment-related changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASES FROM SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ascension Illinois Oncology Research
Hoffman Estates, Illinois, 60169, United States
-
BAMF Health
Grand Rapids, Michigan, 49503, United States
-
Goshen Center for Cancer Care
Goshen, Indiana, 46526, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which steroid works best for brain tumor swelling during radiation? new study aims to find out
- Brain radiation showdown: which technique saves your memory?
- New pill takes aim at hard-to-treat HER2 cancers
- New study aims to uncover why brain radiation affects memory
- New drug AO-252 targets Hard-to-Treat cancers in early trial